You are here

Amarin

ESC 2019 – Amarin hopes for guideline boost despite regulatory delay

ESC 2019 – Amarin hopes for guideline boost despite regulatory delay

EP Vantage

European Society of Cardiology

Flag link:

Amarin's Vascepa buzzkill: FDA stalls label review with surprise panel meeting

Amarin's Vascepa buzzkill: FDA stalls label review with surprise panel meeting

Fierce Pharma

advisory panels

Flag link:

Amarin boosted as another milestone to the FDA’s big Vascepa decision flies by with no sign of an AdCom

Amarin boosted as another milestone to the FDA’s big Vascepa decision flies by with no sign of an AdCom

Endpoints

advisory panels

Flag link:

Amarin: Is a Buyout Really Off the Table?

Amarin: Is a Buyout Really Off the Table?

Yahoo/Motley Fool

Flag link:

Acasti sits pretty as raise brings $400M for Amarin

Acasti sits pretty as raise brings $400M for Amarin

BioWorld

Flag link:

Amarin raises sales guidance for heart drug Vascepa, hires more sales reps for larger marketing push

Amarin raises sales guidance for heart drug Vascepa, hires more sales reps for larger marketing push

Stat

Flag link:

Amarin gets a boost from the FDA as regulators promise speedy Vascepa decision — but what about that panel review?

Amarin gets a boost from the FDA as regulators promise speedy Vascepa decision — but what about that panel review?

Endpoints

Flag link:

Amarin defends Vascepa's CV-prevention data against supplement makers eager to cash in

Amarin defends Vascepa's CV-prevention data against supplement makers eager to cash in

Fierce Pharma

Flag link:

These 6 biotech stocks are promising takeover targets

These 6 biotech stocks are promising takeover targets

Marketwatch

Sarepta Therapeutics

Intercept Pharmaceuticals

Alder Biopharmaceuticals

Flag link:

Amarin takes application to expand Vascepa label to the FDA as M&A chatter heats up

Amarin takes application to expand Vascepa label to the FDA as M&A chatter heats up

Endpoints

Flag link:

Diabetes group nods to Vascepa, sending Amarin stock higher

Diabetes group nods to Vascepa, sending Amarin stock higher

Biopharma Dive

Flag link:

Amarin’s Vascepa prevents second and third heart attacks in analysis, fueling debate

Amarin’s Vascepa prevents second and third heart attacks in analysis, fueling debate

Stat

American College of Cardiology

Flag link:

The Week Ahead In Biotech: Conferences, PDUFA Dates, Clinical Trials And Earnings

The Week Ahead In Biotech: Conferences, PDUFA Dates, Clinical Trials And Earnings

Yahoo/Benzinga

SAGE Therapeutics

Ligand Pharmaceuticals

Jazz Pharmaceuticals

Lexicon Pharmaceuticals

Leap Therapeutics

Flag link:

ACC 2019 preview – Bayer hopes for heart failure panache

ACC 2019 preview – Bayer hopes for heart failure panache

EP Vantage

Flag link:

Is Amarin Sitting on a Goldmine?

Is Amarin Sitting on a Goldmine?

Motley Fool

Flag link:

Would Pfizer Shareholders Win With an Acquisition of Amarin?

Would Pfizer Shareholders Win With an Acquisition of Amarin?

Motley Fool

Flag link:

Pick your post-JPM buzz: Pfizer eyes Amarin, Biogen shops anyone with 'multiple' phase 3 drugs

Pick your post-JPM buzz: Pfizer eyes Amarin, Biogen shops anyone with 'multiple' phase 3 drugs

Fierce Pharma

Flag link:

The winners and losers from JPM 2019

The winners and losers from JPM 2019

Biopharma Dive

SAGE Therapeutics

Flag link:

JP Morgan Healthcare Conference Update: Sage, Mersana, Shutdown Woes and Babies

JP Morgan Healthcare Conference Update: Sage, Mersana, Shutdown Woes and Babies

BioSpace

SAGE Therapeutics

Denali Therapeutics

government shutdown

Flag link:

Pharma's 2019 Prognosis Hinges on These Key Themes

Pharma's 2019 Prognosis Hinges on These Key Themes

Bloomberg

Flag link:

Pages